Validity and reliability of male andropause symptoms self-assessment questionnaire among elderly males in Khuzestan province of Iran

Abdolrahim Asadollahi¹,², Laleh Fani Saberi², Nasrin Faraji³

¹Social Gerontology, Australian Centre on Quality of Life, Deakin University, Melbourne, Australia, ²Department of Community Health, Faculty of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, ³Aging Care Department, Bureau of Prevention and Rehabilitation, Ahwaz, Iran

ABSTRACT

Background: Andropause is a condition of decreasing testosterone in men that usually begins to occur at about 40 years of age. Many men find it difficult to acknowledge there may be a problem by refusing to even talk about the symptoms.

Aims: The study was conducted to the standards of MASSQ (2012) within male older adults to introduce a relevant criterion.

Materials and Methods: About 382 men with age range of 50-80 and with the mean age of 65.3 ± 2.32 were sampled with the cluster-ratio sampling method from the eight cities of Khuzestan province in southwestern Iran. The aged samples replied to the 25 items of MASSQ.

Results: Coefficients of Cronbach’s alpha (α = 0.89), split-half (0.91), convergent validity (0.72), divergent validity (~0.32), and criterion validity (0.67) were estimated, which were significant at P < 0.01. The exploratory factor analysis demonstrated that the 25-items of MASSQ for aged samples are organized into four factors (sexual, somatic, psychic, and behavioral) which clarify 79% of the scale’s variance. Second-order confirmatory factor analysis pointed out that the factors are well-matched up onto a principal factor. Consequently, the four-factor model was well appropriate for the data by the fit index techniques for adjusting the scale [adjusted goodness of fit index = 0.92, goodness-of-fit statistic = 0.91, root mean square error of approximation = 0.006, incremental fit index = 0.94, normed fit index = 0.91, comparative fit index = 0.97].

Conclusions: The results pointed to the well-adjusted reliability and validity of MASSQ and its usefulness for the relevant studies as well.

Key Words: Ahwaz metropolis, andropause, elderly men, Iran, male andropause symptoms self-assessment questionnaire, validity and reliability

INTRODUCTION

Andropause is a condition of decreasing testosterone in men that usually begins to occur at about 40 years of age. Many men also find it difficult to acknowledge there may be a problem by refusing to even talk about the symptoms. Ignorance and fear of the andropause condition abounds in the general public and even among health professionals. Over 10,000 articles on climacteric (or menopause) for women can be found but relatively less has been conducted on the male equivalent.

The ratio of published studies of menopausal men to menopausal women is approximately 1:100. Attaining knowledge regarding andropause will help the caregivers and gerontologists to achieve the ultimate goal of a dignified healthy ageing and maintain the highest quality of life. Thus, it’s adding life to years and not simply years to life. While ignorance about
andropause persists, having an instrument turns out to be a necessity. It’s helpful even in the clinical treatment as well. The study was investigated to the standards of MASSQ (2012) within male older adults to introduce a relevant criterion.

MATERIALS AND METHODS

About 382 men with age range of 50-80 and with the mean age of 65.3 ± 2.32 were sampled with the cluster-ratio sampling method from the eight cities of Khuzestan province in southwestern Iran (N = 228784 aged persons in the province) [Appendix 1]. The aged samples replied to the 25 items of MASSQ. The MASSQ questionnaire mainly consists of a 25-item disability/symptom scale regarding andropause that was investigated by authors and literature reviews. Each item in the disability/symptom scale has five response options from 1 = none to 5 = extremely severe. If the 25 items are completed, a scale score ranging from 25 (no symptoms) to 125 (most severe symptoms) can be calculated.

Translating the instrument

The questionnaire was translated into Persian from its English version by three instructors and an English language expert. The four translated versions were compared by the authors, and the researchers developed a common Persian text from them. Afterward, the Persian version of the MASSQ was translated back into English by an English language expert who had not seen the original English text and by a linguist. The English statements of the questionnaire that had been translated from Persian into English were compared with the original version, and any necessary revisions were made as well.

Setting and participants

From the eight cities of Khuzestan province in southwestern Iran, that is, Ahwaz, Behbahan, Dezful, Shoushtar, Abadan, Mah-Shahr, Masjid Soleiman, and Ramhormoz, about 400 aged men responded to the Iranian version of the MASSQ. Of the 400 responders, 382 had responded.

Table 1: Varimax-rotated factors matrix of the MASSQ†

| No. of item | Item                                                                 | Mean | SD  | Components (Factor) |
|-------------|----------------------------------------------------------------------|------|-----|---------------------|
| 19          | I have decreased sex drive (libido)                                 | 0.40 | 0.49| 0.89                |
| 22          | I notice a decrease in my ability to play sports                    | 0.29 | 0.46| 0.84                |
| 23          | I am sadder and/or more grumpy than usual                          | 0.31 | 0.47| 0.85                |
| 24          | I notice a lack of energy                                          | 0.31 | 0.47| 0.88                |
| 25          | Decrease in ability/frequency to perform sexually                  | 0.16 | 0.47| 0.91                |
| 1           | Decline in feeling of general well-being (general state of health, subjective feeling) | 0.33 | 0.49| 0.92                |
| 14          | Decrease in beard growth                                          | 0.36 | 0.43| 0.92                |
| 17          | I feel like I’m losing height                                     | 0.09 | 0.47| 0.89                |
| 18          | I notice a decrease in strength and endurance                      | 0.33 | 0.48| 0.89                |
| 20          | I notice a decrease in my ability to play sports                   | 0.24 | 0.24| 0.90                |
| 1           | Decline in feeling of general well-being (general state of health, subjective feeling) | 0.28 | 0.47| 0.87                |
| 6           | Irritability (feeling aggressive, easily upset about little things, moody) | 0.17 | 0.43| 0.87                |
| 7           | Nervousness (inner tension, restlessness, feeling fidgety)         | 0.09 | 0.38| 0.88                |
| 8           | Anxiety (feeling panicky)                                         | 0.09 | 0.28| 0.89                |
| 11          | Depressive mood (feeling down, sad, on the verge of tears, lack of drive, mood swings, feeling nothing is of any use) | 0.24 | 0.28| 0.88                |
| 12          | Feeling that you have passed your peak                             | 0.26 | 0.43| 0.86                |
| 4           | Sleep problems (difficulty in falling asleep, difficulty in sleeping through, waking up early and feeling tired, poor sleep, sleeplessness) | 0.24 | 0.44| 0.87                |
| 5           | Increased need for sleep, often feeling tired                      | 0.27 | 0.38| 0.88                |
| 15          | I fall asleep after dinner                                       | 0.31 | 0.46| 0.90                |
| 21          | I am sadder and/or more grumpy than usual                         | 0.33 | 0.31| 0.89                |

†Item responses were coded as 1 “none,” 2 “mild,” 3 “moderate,” 4 “severe,” and 5 “extremely severe,” reflecting the presence or absence of a symptom over the past year.

SD: standard deviation
Asadollahi, et al.: Validity and reliability of male andropause questionnaire

**Table 2: The goodness of fit indexes model**

| Indexes | $\chi^2$ | df | $\chi^2$/df | AGFI | GFI | RMSEA | IFI | NFI | CFI |
|---------|---------|----|-------------|------|-----|-------|-----|-----|-----|
| Value   | 321.94  | 284| 1.13        | 0.92 | 0.91| 0.006 | 0.94| 0.91| 0.97|

**RESULTS**

Coefficients of Cronbach's alpha ($\alpha = 0.89$), split-half (0.91), convergent validity (0.72), divergent validity (-0.32) criterion validity (0.67) were estimated, which were significant at $P < 0.01$. The exploratory factor analysis demonstrated that the 25-items of MASSQ for aged samples are organized into four factors (Factor 1: Sexual, Factor 2: Somatic, Factor 3: Psychic, and Factor 4: Behavioral) which clarify 83% of the scale's variance. Second-order confirmatory factor analysis pointed out that the factors were well matched up onto a principal factor. According to the Table 1, the rotated factor matrix pattern of varimax for the MASSQ's subscale questions was considered. Those questions with factor loadings above 0.75 were selected.

Consequently, the four-factor model was appropriate for the data and the fit index techniques for adjusting the scale. The indexes of the model's goodness of fit refer to the integrity of the four-factor model with data. The $\chi^2$ to degrees of freedom is less than 2 in efficient models. It's closer to 0 and will be closer. The root mean square error of approximation (RMSEA) and standardized root mean residual (SRMR) must be less than 0.05 that indicate to good models. The model pointed out the goodness of fit of the model in the study (AGFI = 0.92, GFI = 0.91, RMSEA = 0.006, IFI = 0.94, NFI = 0.91, CFI = 0.97).

As closer measure to 1 in the normed fit index (NFI), the comparative fit index (CFI), goodness-of-fit statistic (GFI), the incremental fit index (IFI), and the adjusted goodness of fit index (AGFI), they refer to the goodness and fit of model. They were more than 0.90 [Table 2].

**DISCUSSION AND CONCLUSION**

The aim of the study is to look for the relevant instrument regarding common symptoms of an aged-related issue called andropause within aged males in the Iranian social context,[35-36] even the issue still is challengeable.[34,9,12,19,20,26] So, the andropause symptoms self-assessment questionnaire (MASSQ, 2012) was used and evaluated. The results stated to the well-adjusted reliability and validity of MASSQ and usefulness of it in the relevant studies as well. Therefore, future researchers should not limit themselves to the western scales[7,20] but should also consider specific cultural factors. Additionally, it is suggested that in future studies, the female menopause symptoms self-assessment questionnaire, which are compatible with Iran's native culture, be conducted and evaluated as well.

Regarding the findings of the study, the MASSQ is appropriate for? Validity and reliability in the aged male community of the Iranian society and it can be employed to measure andropause symptoms. It is applicable by gerontologists for the future studies as well as to the geriatrics in their diagnostics.

**Ethical considerations**

Ethical matters, for example, plagiarism, uninformed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, and so on, have been totally observed by the authors.

**APPENDIX**

Male andropause symptoms self-assessment questionnaire

In all men, their levels of testosterone begin to decline from the age of about 25 and continue to decline throughout their lives. For many men, this dramatic but gradual decline in testosterone levels does not seem to have any effect on them whatsoever and they sail along unconcerned and unperturbed by any decline in their sexual drive or performance. But for some men hormonal decline can have quite profound negative effects. The most usual manifestation of this is a fall in sexual inclinations or libido. Andropause is a condition of low testosterone in men that usually begins to occur at about 40 years of age. Andropause is often misdiagnosed or not diagnosed at all for several reasons. The primary reason is the severity and frequency of symptoms can vary dramatically from man to man. Many men also find it difficult to acknowledge there may be a problem by even talking about symptoms. Finally, healthcare providers often conclude symptoms are related to aging or a medical condition such as depression rather than to low testosterone. Take our simple assessment to identify the most common symptoms of andropause and rate the severity of your symptoms. Simply check one box for each symptom in the assessment below. The following form will help you determine if you suffer from the male menopause and whether to consider testosterone therapy method as a treatment option.[2,12]
### INTERPRETING THE RESULTS

How did you score? Cross reference your score with the table below.

| Final score | Likelihood of male menopause |
|-------------|-----------------------------|
| Less than 40 | You probably don’t need testosterone therapy |
| 40-84 | You might benefit from testosterone therapy |
| Greater than 85 | You almost certainly would benefit from testosterone replacement therapy |

### REFERENCES

1. Olarinoye JK, Adebisi SA, Popoola AA. Andropause: An emerging world health problem. West Afr J Med 2006;25:84-7.
2. Harrison J. Talking about my generation: A state-of-the-art review of health information for men in the andropause. Health Info Libr J 2011;28:161-70.
3. Bain J, Brock G, Kuzmarov I. International Consulting Group. Canadian Society for the Study of the Aging Male: Response to health Canada’s position paper on testosterone treatment. J Sex Med 2007;4:558-66.
4. Staerman F, Léon P. Andropause (androgen deficiency of the aging male): Diagnosis and management. Minerva Med 2012;103:333-42.
5. Rice D, Brannigan RE, Campbell RK, Fine S, Jack L Jr, Nelson JB, Regan-Klich J. Men’s health, low testosterone, and diabetes: Individualized treatment and a multidisciplinary approach. Diabetes Educ 2008;34 Supp 15:97-112S.
6. Milewicz A. Menopausal obesity and metabolic syndrome-PoliSenior study. Minerva Endocrinol 2012;37:93-101.
7. Kolovou G, Bilianou H, Marvaki A, Mikhailidis DP. Aging men and lipids. Am J Mens Health 2011;5:152-65.
8. Adebajo S, Odeyemi K, Anorlu R, Wright L. Knowledge and experiences of Andropause among men in Lagos, Nigeria. West Af J Med 2007;26:106-12.
9. Holm AC, Fredrikson MG. More than half of the men in a Swedish population of men aged 55, 65 and 75 believe in ‘a male climacteric’. Aging Male 2011;14:16-20.
10. Yan YY. Awareness and knowledge of andropause among Chinese males in Hong Kong. Am J Mens Health 2010;4:231-6.
11. Hirokawa K, Taniguchi T, Fujii Y, Takaki J, Tsutsumi A. Job demands as a potential modifier of the association between testosterone deficiency and andropause symptoms in Japanese middle-aged workers: A cross-sectional study. Maturitas 2012;73:225-9.
12. Guo Y, Li H. Male Climacteric Syndrome (andropause). Zhonghua Nan Ke Xue 2004;10:563-6.
13. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 2009;21:24-36.
14. Noh YH, Kim DH, Kim JY, Park J, Kim OH, Han D, et al. Improvement of andropause symptoms by dandelion and rooibos extract complex CRS-10 in aging male. Nutr Res Pract 2012;6:505-12.
15. Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol 2007;156:585-94.
16. Llaneza P, García-Portilla MP, Llaneza-Suárez D, Arnett B, Pérez-López FR. Depressive disorders and the menopause transition. Maturitas 2012;71:120-30.
17. Fatusi AO, Ijadunola KT, Ojofetimi EO, Adeyemi MO, Omideyi AK, Akinyemi A, et al. Assessment of andropause awareness and erectile dysfunction among married men in Ille-Ife, Nigeria. Aging Male 2003;8:79-85.
18. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci 2012;67:1140-52.
19. Marvan ML, Castillo-López RL, Arroyo L. Mexican beliefs and attitudes toward menopause and menopausal-related symptoms. J Psychosom Obstet Gynaecol 2013;34:39-45.
20. Pines A. Male menopause: Is it a real clinical syndrome? Climacteric 2011;14:15-7.
21. Maha AS. Prevalence of andropausal symptoms among kuwaiti males. Am J Mens Health 2013;7:516-22.
22. Pommerville PJ, Zakus P. Knowledge and awareness among primary care physicians in Victoria, BC, Canada. Aging Male 2006;9:215-20.
23. Stefanek E, Strohmeier D, Fandrem H, Spiel C. Depressive symptoms in native and immigrant adolescents: The role of critical life events and daily hassles. Anxiety Stress Coping 2012;25:201-17.

24. Zengerling F, Schrader AJ, Cronauer MV, Stemann H, Schrader M, Rinnab L. The “Aging Males’ Symptoms” Scale (AMS): Predictive value for lowered circulating androgens. Aging Male 2012;15:253-7.

25. Samaras N, Samaras D, Lang PO, Forster A, Pichard C, Frangos E, et al. A view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes? Maturitas 2012.

26. Lang PO, Samaras D, Samaras N. Testosterone replacement therapy in reversing “Andropause”: What is the proof-of-principle? Rejuvenation Res 2012;15:453-65.

27. Gould DC, Petty R. The male menopause: Does it exist? for: Some men need investigation and testosterone treatment. West J Med 2000;173:76-8.

28. Beg S, Al-Khoury L, Cunningham GR. Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes 2008;15:364-70.

29. Chedraui P, Pérez-López FR, Sánchez H, Aguirre W, Martínez N, Miranda O, et al. Assessment of sexual function of mid-aged Ecuadorian women with the 6-item Female Sexual Function Index. Maturitas 2012;71:407-12.

30. Chen CY, Lee CP, Chen Y, Jiang JR, Chu CL, Chen CL. The correlation between emotional distress and aging males’ symptoms at a psychiatric outpatient clinic: Sexual dysfunction as a distinguishing characteristic between Andropause and anxiety/depression in aging men. Clin Interv Aging 2013;8:635-40.

31. Chen RY, Ng KK. Self-referred older Asian males in a men’s health clinic: The inter-relationships between androgens, metabolic parameters and quality of life measures. Aging Male 2010;13:233-41.

32. Chueh KS, Huang SP, Lee YC, Wang CJ, Yeh HC, Li WM, et al. The comparison of the aging male symptoms (AMS) scale and androgen deficiency in the aging male (ADAM) questionnaire to detect androgen deficiency in middle-aged men. J Androl 2012;33:817-23.

33. Grunfeld EA, Halliday A, Martin P, Drudge-Coates L. Andropause syndrome in men treated for metastatic prostate cancer: A qualitative study of the impact of symptoms. Cancer Nurs. 2012;35:63-9.

34. Fukui M, Tanaka M, Toda H, Okada H, Ohnishi M, Mogami S, et al. Andropausal symptoms in men with Type 2 diabetes. Diabet Med 2012;29:1036-42.

35. All Saints Clinic. Male Menopause (Andropause) Symptoms Self-Assessment Questionnaire. Retrieved August 19, 2013. Available from: http://www.allsaintsclinic.org/andropause-male-menopause-test.shtml [Last updated on 2012 Apr 4; Last cited on 2012 Apr 3].

36. Asadollahi A. Social quality and Social Well-being for Aged People; toward measuring and understanding in community level, Saarbrucken, Germany: Lambert Academic Pub. Co.; 2011.

How to cite this article: Asadollahi A, Saberi LF, Faraji N. Validity and reliability of male andropause symptoms self-assessment questionnaire among elderly males in Khuzestan province of Iran. J Mid-life Health 2013;4:233-7.

Source of Support: Nil, Conflict of Interest: None declared.